IN2012DN00765A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00765A
IN2012DN00765A IN765DEN2012A IN2012DN00765A IN 2012DN00765 A IN2012DN00765 A IN 2012DN00765A IN 765DEN2012 A IN765DEN2012 A IN 765DEN2012A IN 2012DN00765 A IN2012DN00765 A IN 2012DN00765A
Authority
IN
India
Prior art keywords
medicament
compound
formula
well
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
Li Chen
Lichun Feng
Mengwei Huang
Jia Li
Fajun Nan
Tao Pang
Lifang Yu
Mei Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN00765A publication Critical patent/IN2012DN00765A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
IN765DEN2012 2009-09-21 2010-09-20 IN2012DN00765A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2009/074060 WO2011032320A1 (en) 2009-09-21 2009-09-21 Novel alkene oxindole derivatives
PCT/EP2010/063770 WO2011033099A1 (en) 2009-09-21 2010-09-20 Alkene oxindole derivatives and their uses to treat obesity, diabetes and hyperlipidemia

Publications (1)

Publication Number Publication Date
IN2012DN00765A true IN2012DN00765A (ru) 2015-06-26

Family

ID=43414813

Family Applications (1)

Application Number Title Priority Date Filing Date
IN765DEN2012 IN2012DN00765A (ru) 2009-09-21 2010-09-20

Country Status (10)

Country Link
US (3) US20110071195A1 (ru)
EP (1) EP2480530A1 (ru)
JP (1) JP2013505281A (ru)
KR (1) KR20120068876A (ru)
AU (1) AU2010297252A1 (ru)
BR (1) BR112012006172A2 (ru)
CA (1) CA2772674A1 (ru)
IN (1) IN2012DN00765A (ru)
MX (1) MX2012002477A (ru)
WO (2) WO2011032320A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
WO2013119774A1 (en) * 2012-02-10 2013-08-15 Virginia Commonwealth University 3-(2-amino-ethyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-alkylidene-1,3-dihydro-indol-2-one derivatives as selective sphingosine kinase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2769974A1 (en) * 2013-02-21 2014-08-27 Debiopharm S.A. Novel AMPK activator
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
EP3010903A1 (en) * 2013-06-20 2016-04-27 Boehringer Ingelheim International GmbH Olefin substituted oxindoles having ampk activity
EP2886541A1 (en) * 2013-12-19 2015-06-24 Sanofi Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases
ES2567105B1 (es) * 2014-09-19 2017-02-10 Consejo Superior De Investigaciones Científicas (Csic) Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados
CN106619616A (zh) * 2015-11-04 2017-05-10 中国科学院上海药物研究所 3-烯基吲哚酮类衍生物在制备治疗miri药物中的用途及其药物组合物
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243034T1 (de) * 1996-01-17 2003-07-15 Taiho Pharmaceutical Co Ltd Intimale verdickungsinhibitoren
ES2239393T3 (es) * 1997-05-07 2005-09-16 Sugen, Inc. Derivados de 2-indolinona utilizados como moduladores de la actividad de la proteina-quinasa.
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
TW200745033A (en) * 2005-09-14 2007-12-16 Dainippon Sumitomo Pharma Co Oxindole derivative as feeding control agent
CN101553482B (zh) * 2006-09-15 2013-11-20 艾科睿制药公司 激酶抑制剂化合物
WO2009076631A1 (en) * 2007-12-12 2009-06-18 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
US8273744B2 (en) * 2008-02-04 2012-09-25 Mercury Therapeutics, Inc. AMPK modulators
WO2010051206A1 (en) * 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives

Also Published As

Publication number Publication date
US20110071195A1 (en) 2011-03-24
US20140288127A1 (en) 2014-09-25
BR112012006172A2 (pt) 2016-05-31
CA2772674A1 (en) 2011-03-24
AU2010297252A1 (en) 2012-02-02
US20130131114A1 (en) 2013-05-23
EP2480530A1 (en) 2012-08-01
WO2011033099A1 (en) 2011-03-24
WO2011032320A1 (en) 2011-03-24
JP2013505281A (ja) 2013-02-14
MX2012002477A (es) 2012-03-26
US8778973B2 (en) 2014-07-15
KR20120068876A (ko) 2012-06-27

Similar Documents

Publication Publication Date Title
IN2012DN00765A (ru)
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
MX2022007264A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
UA108105C2 (ru) Азотсодержащие гетероарильные соединения
MX342440B (es) Derivados fluorados de aminotriazol.
IN2012DN03337A (ru)
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
MY153985A (en) Aminotriazole derivatives as alx agonists
MX2011011094A (es) Derivados de prolina como inhibidores de catepsina.
ZA201002987B (en) Tropane compounds
MY183312A (en) Pharmaceutical formulation
UA109037C2 (ru) Триазолопиридины
IN2012DN03182A (ru)
IN2012DN01232A (ru)
MX2014004920A (es) Nuevos derivados de pirazina.
PH12015502429A1 (en) Dicarboxylic acid compound
NZ595705A (en) Protease inhibitors
JO2781B1 (en) A new process for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acid.
MX2015015755A (es) Derivados de perhidroquinoxalina utiles como analgesicos.
IN2014DN10669A (ru)
MX2013008256A (es) Derivados novedosos de tetrahidroquinolina.
MX2011011716A (es) Derivados de isoquinolina novedosos.
MX346090B (es) Derivados de pirrolidina usados como inhibidores de catepsina.
JO2782B1 (en) A new process for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acid.
MX2013002694A (es) Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.